^
Association details:
| Biomarker: | RUNX1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
Published date:
05/26/2022
Excerpt:
The ORR was 62%,with six pts reaching complete response (CR),four pts reaching marrow CR and three pts achieved marrow CR+ hematologic improvement (HI)...In these 21 pts, the most frequently mutated genes are ASXL1 (28.6%), RUNX1 (14.3%) and TET2 (14.3%)...This is the first study to evaluate the efficacy and safety of sintilimab plus decitabine in pts with untreated higher-risk MDS. The preliminary results demonstrate that the combination therapy is relatively safe with anti-tumor activity.
Secondary therapy:
decitabine
DOI:
10.1200/JCO.2022.40.16_suppl.7052
